501. Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model
- Author
-
Johannes Kuehle, Morgan L. Maeder, Heimo Riedel, Jamal Alzubi, Tobias Cantz, Claudio Mussolino, Paul Fisch, Christian Reimann, Tafadzwa Mlambo, Axel Schambach, J. Keith Joung, Shamim H. Rahman, Cornelia Rudolph, and Toni Cathomen
- Subjects
Male ,Cancer Research ,lcsh:QH426-470 ,Genotyping Techniques ,T-Lymphocytes ,Genetic enhancement ,Cellular differentiation ,Induced Pluripotent Stem Cells ,DNA-Activated Protein Kinase ,Biology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Genome editing ,Genetics ,medicine ,Animals ,Humans ,Induced pluripotent stem cell ,Molecular Biology ,Genetics (clinical) ,Ecology, Evolution, Behavior and Systematics ,030304 developmental biology ,0303 health sciences ,Severe combined immunodeficiency ,Genome ,HEK 293 cells ,Nuclear Proteins ,Gene targeting ,Cell Differentiation ,Zinc Fingers ,Fibroblasts ,medicine.disease ,3. Good health ,Cell biology ,DNA-Binding Proteins ,lcsh:Genetics ,Disease Models, Animal ,HEK293 Cells ,Phenotype ,NIH 3T3 Cells ,Signal transduction ,Protein Kinases ,030217 neurology & neurosurgery ,Research Article ,Signal Transduction - Abstract
In vitro disease modeling based on induced pluripotent stem cells (iPSCs) provides a powerful system to study cellular pathophysiology, especially in combination with targeted genome editing and protocols to differentiate iPSCs into affected cell types. In this study, we established zinc-finger nuclease-mediated genome editing in primary fibroblasts and iPSCs generated from a mouse model for radiosensitive severe combined immunodeficiency (RS-SCID), a rare disorder characterized by cellular sensitivity to radiation and the absence of lymphocytes due to impaired DNA-dependent protein kinase (DNA-PK) activity. Our results demonstrate that gene editing in RS-SCID fibroblasts rescued DNA-PK dependent signaling to overcome radiosensitivity. Furthermore, in vitro T-cell differentiation from iPSCs was employed to model the stage-specific T-cell maturation block induced by the disease causing mutation. Genetic correction of the RS-SCID iPSCs restored T-lymphocyte maturation, polyclonal V(D)J recombination of the T-cell receptor followed by successful beta-selection. In conclusion, we provide proof that iPSC-based in vitro T-cell differentiation is a valuable paradigm for SCID disease modeling, which can be utilized to investigate disorders of T-cell development and to validate gene therapy strategies for T-cell deficiencies. Moreover, this study emphasizes the significance of designer nucleases as a tool for generating isogenic disease models and their future role in producing autologous, genetically corrected transplants for various clinical applications., Author Summary Due to the limited availability and lifespan of some primary cells, in vitro disease modeling with induced pluripotent stem cells (iPSCs) offers a valuable complementation to in vivo studies. The goal of our study was to establish an in vitro disease model for severe combined immunodeficiency (SCID), a group of inherited disorders of the immune system characterized by the lack of T-lymphocytes. To this end, we generated iPSCs from fibroblasts of a radiosensitive SCID (RS-SCID) mouse model and established a protocol to recapitulate T-lymphopoiesis from iPSCs in vitro. We used designer nucleases to edit the underlying mutation in prkdc, the gene encoding DNA-PKcs, and demonstrated that genetic correction of the disease locus rescued DNA-PK dependent signaling, restored normal radiosensitivity, and enabled T-cell maturation and polyclonal T-cell receptor recombination. We hence provide proof that the combination of two promising technology platforms, iPSCs and designer nucleases, with a protocol to generate T-cells in vitro, represents a powerful paradigm for SCID disease modeling and the evaluation of therapeutic gene editing strategies. Furthermore, our system provides a basis for further development of iPSC-derived cell products with the potential for various clinical applications, including infusions of in vitro derived autologous T-cells to stabilize patients after hematopoietic stem cell transplantation.
- Published
- 2015
- Full Text
- View/download PDF